About us

Ganymed Pharmaceuticals AG is a leading biopharmaceutical company focusing on the development  of a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs) for the treatment of solid cancers. Ganymed was founded in 2001 as a spin-off from the Universities of Mainz and Zurich and is named after Jupiter’s largest moon on which the Galileo spacecraft discovered in late 2000 hidden oceans of salty water that may support life.

Ganymed is located in Mainz, Germany and occupies state-of-the-art facilities which include laboratories for antibody development and biomarker discovery. The company currently employs approximately 80 people dedicated to research, clinical trials and product development.